#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=The Mechanism of Action
2-1	3-6	The	event[1]	new[1]	_	_
2-2	7-16	Mechanism	event[1]	new[1]	_	_
2-3	17-19	of	event[1]	new[1]	_	_
2-4	20-26	Action	event[1]|abstract	new[1]|new	_	_

#Text=Only Lucilia sericata larvae from certified farms can be safely used in medicine .
3-1	27-31	Only	_	_	_	_
3-2	32-39	Lucilia	_	_	_	_
3-3	40-48	sericata	animal[3]	new[3]	coref	7-4[0_3]
3-4	49-55	larvae	animal[3]	new[3]	_	_
3-5	56-60	from	animal[3]	new[3]	_	_
3-6	61-70	certified	animal[3]|place[4]	new[3]|new[4]	_	_
3-7	71-76	farms	animal[3]|place[4]	new[3]|new[4]	_	_
3-8	77-80	can	_	_	_	_
3-9	81-83	be	_	_	_	_
3-10	84-90	safely	_	_	_	_
3-11	91-95	used	_	_	_	_
3-12	96-98	in	_	_	_	_
3-13	99-107	medicine	substance	new	_	_
3-14	108-109	.	_	_	_	_

#Text=Complicated procedures of egg disinfection , using chloroamine , povidone-iodine and sodium hypochlorite , are intended to ensure safety during use of this product .
4-1	110-121	Complicated	abstract[6]	new[6]	_	_
4-2	122-132	procedures	abstract[6]	new[6]	_	_
4-3	133-135	of	abstract[6]	new[6]	_	_
4-4	136-139	egg	abstract[6]|object|abstract[8]	new[6]|new|new[8]	_	_
4-5	140-152	disinfection	abstract[6]|abstract[8]	new[6]|new[8]	_	_
4-6	153-154	,	_	_	_	_
4-7	155-160	using	_	_	_	_
4-8	161-172	chloroamine	substance	new	_	_
4-9	173-174	,	_	_	_	_
4-10	175-190	povidone-iodine	substance	new	_	_
4-11	191-194	and	_	_	_	_
4-12	195-201	sodium	substance|substance[12]	new|new[12]	_	_
4-13	202-214	hypochlorite	substance[12]	new[12]	_	_
4-14	215-216	,	_	_	_	_
4-15	217-220	are	_	_	_	_
4-16	221-229	intended	_	_	_	_
4-17	230-232	to	_	_	_	_
4-18	233-239	ensure	_	_	_	_
4-19	240-246	safety	abstract	new	_	_
4-20	247-253	during	_	_	_	_
4-21	254-257	use	abstract[14]	new[14]	_	_
4-22	258-260	of	abstract[14]	new[14]	_	_
4-23	261-265	this	abstract[14]|substance[15]	new[14]|new[15]	_	_
4-24	266-273	product	abstract[14]|substance[15]	new[14]|new[15]	_	_
4-25	274-275	.	_	_	_	_

#Text=MDT is based on three mechanisms , observed when Lucilia sericata are introduced to the wound : the mechanical removal of necrotic tissue , bactericidal and bacteriostatic activity , and promotion of the healing process .
5-1	276-279	MDT	event	new	_	_
5-2	280-282	is	_	_	_	_
5-3	283-288	based	_	_	_	_
5-4	289-291	on	_	_	_	_
5-5	292-297	three	abstract[17]	new[17]	_	_
5-6	298-308	mechanisms	abstract[17]	new[17]	_	_
5-7	309-310	,	_	_	_	_
5-8	311-319	observed	_	_	_	_
5-9	320-324	when	_	_	_	_
5-10	325-332	Lucilia	_	_	_	_
5-11	333-341	sericata	_	_	_	_
5-12	342-345	are	_	_	_	_
5-13	346-356	introduced	_	_	_	_
5-14	357-359	to	_	_	_	_
5-15	360-363	the	abstract[18]	new[18]	coref	6-12[28_18]
5-16	364-369	wound	abstract[18]	new[18]	_	_
5-17	370-371	:	_	_	_	_
5-18	372-375	the	event[19]	new[19]	_	_
5-19	376-386	mechanical	event[19]	new[19]	_	_
5-20	387-394	removal	event[19]	new[19]	_	_
5-21	395-397	of	event[19]	new[19]	_	_
5-22	398-406	necrotic	event[19]|object[20]	new[19]|new[20]	coref	13-9[0_20]
5-23	407-413	tissue	event[19]|object[20]	new[19]|new[20]	_	_
5-24	414-415	,	event[19]	new[19]	_	_
5-25	416-428	bactericidal	event[19]	new[19]	_	_
5-26	429-432	and	event[19]	new[19]	_	_
5-27	433-447	bacteriostatic	event[19]|abstract[21]	new[19]|new[21]	_	_
5-28	448-456	activity	event[19]|abstract[21]	new[19]|new[21]	_	_
5-29	457-458	,	_	_	_	_
5-30	459-462	and	_	_	_	_
5-31	463-472	promotion	event[22]	new[22]	_	_
5-32	473-475	of	event[22]	new[22]	_	_
5-33	476-479	the	event[22]|abstract[24]	new[22]|new[24]	coref	7-6[37_24]
5-34	480-487	healing	event[22]|object|abstract[24]	new[22]|new|new[24]	coref	12-11
5-35	488-495	process	event[22]|abstract[24]	new[22]|new[24]	_	_
5-36	496-497	.	_	_	_	_

#Text=Reports from the last decade point out that physical contact with the wound is a less important effect of the larval presence within the wound , and is probably a negative effect for the patient , who may feel a physical presence and wiggling in the wound .
6-1	498-505	Reports	abstract[25]	new[25]	_	_
6-2	506-510	from	abstract[25]	new[25]	_	_
6-3	511-514	the	abstract[25]	new[25]	_	_
6-4	515-519	last	abstract[25]	new[25]	_	_
6-5	520-526	decade	abstract[25]|time	new[25]|new	_	_
6-6	527-532	point	abstract[25]	new[25]	_	_
6-7	533-536	out	_	_	_	_
6-8	537-541	that	_	_	_	_
6-9	542-550	physical	abstract[27]	new[27]	coref	6-15[29_27]
6-10	551-558	contact	abstract[27]	new[27]	_	_
6-11	559-563	with	abstract[27]	new[27]	_	_
6-12	564-567	the	abstract[27]|abstract[28]	new[27]|giv[28]	coref	6-24[31_28]
6-13	568-573	wound	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
6-14	574-576	is	_	_	_	_
6-15	577-578	a	abstract[29]	giv[29]	_	_
6-16	579-583	less	abstract[29]	giv[29]	_	_
6-17	584-593	important	abstract[29]	giv[29]	_	_
6-18	594-600	effect	abstract[29]	giv[29]	_	_
6-19	601-603	of	abstract[29]	giv[29]	_	_
6-20	604-607	the	abstract[29]|abstract[30]	giv[29]|new[30]	coref	6-40[33_30]
6-21	608-614	larval	abstract[29]|abstract[30]	giv[29]|new[30]	_	_
6-22	615-623	presence	abstract[29]|abstract[30]	giv[29]|new[30]	_	_
6-23	624-630	within	abstract[29]|abstract[30]	giv[29]|new[30]	_	_
6-24	631-634	the	abstract[29]|abstract[30]|abstract[31]	giv[29]|new[30]|giv[31]	coref	6-46[34_31]
6-25	635-640	wound	abstract[29]|abstract[30]|abstract[31]	giv[29]|new[30]|giv[31]	_	_
6-26	641-642	,	abstract[29]	giv[29]	_	_
6-27	643-646	and	abstract[29]	giv[29]	_	_
6-28	647-649	is	abstract[29]	giv[29]	_	_
6-29	650-658	probably	abstract[29]	giv[29]	_	_
6-30	659-660	a	abstract[29]	giv[29]	_	_
6-31	661-669	negative	abstract[29]	giv[29]	_	_
6-32	670-676	effect	abstract[29]	giv[29]	_	_
6-33	677-680	for	abstract[29]	giv[29]	_	_
6-34	681-684	the	abstract[29]|person[32]	giv[29]|new[32]	_	_
6-35	685-692	patient	abstract[29]|person[32]	giv[29]|new[32]	_	_
6-36	693-694	,	_	_	_	_
6-37	695-698	who	_	_	_	_
6-38	699-702	may	_	_	_	_
6-39	703-707	feel	_	_	_	_
6-40	708-709	a	abstract[33]	giv[33]	_	_
6-41	710-718	physical	abstract[33]	giv[33]	_	_
6-42	719-727	presence	abstract[33]	giv[33]	_	_
6-43	728-731	and	_	_	_	_
6-44	732-740	wiggling	_	_	_	_
6-45	741-743	in	_	_	_	_
6-46	744-747	the	abstract[34]	giv[34]	coref	7-15[0_34]
6-47	748-753	wound	abstract[34]	giv[34]	_	_
6-48	754-755	.	_	_	_	_

#Text=Chemicals secreted by larvae initiate the process of bacterial elimination and remodeling of the wound bed .
7-1	756-765	Chemicals	substance	new	_	_
7-2	766-774	secreted	_	_	_	_
7-3	775-777	by	_	_	_	_
7-4	778-784	larvae	animal	giv	coref	10-5[50_0]
7-5	785-793	initiate	_	_	_	_
7-6	794-797	the	abstract[37]	giv[37]	coref	12-8[69_37]
7-7	798-805	process	abstract[37]	giv[37]	_	_
7-8	806-808	of	abstract[37]	giv[37]	_	_
7-9	809-818	bacterial	abstract[37]|substance|event[39]	giv[37]|new|new[39]	_	_
7-10	819-830	elimination	abstract[37]|event[39]	giv[37]|new[39]	_	_
7-11	831-834	and	abstract[37]	giv[37]	_	_
7-12	835-845	remodeling	abstract[37]|abstract[40]	giv[37]|new[40]	_	_
7-13	846-848	of	abstract[37]|abstract[40]	giv[37]|new[40]	_	_
7-14	849-852	the	abstract[37]|abstract[40]|object[42]	giv[37]|new[40]|new[42]	coref	14-5[81_42]
7-15	853-858	wound	abstract[37]|abstract[40]|abstract|object[42]	giv[37]|new[40]|giv|new[42]	coref	9-7[47_0]
7-16	859-862	bed	abstract[37]|abstract[40]|object[42]	giv[37]|new[40]|new[42]	_	_
7-17	863-864	.	_	_	_	_

#Text=Figure 1
8-1	865-871	Figure	object[43]	new[43]	_	_
8-2	872-873	1	object[43]	new[43]	_	_

#Text=shows the effect of debridement on a necrotic forearm wound measuring over 200 cm² .
9-1	874-879	shows	_	_	_	_
9-2	880-883	the	abstract[44]	new[44]	_	_
9-3	884-890	effect	abstract[44]	new[44]	_	_
9-4	891-893	of	abstract[44]	new[44]	_	_
9-5	894-905	debridement	abstract[44]|event	new[44]|new	coref	18-14
9-6	906-908	on	_	_	_	_
9-7	909-910	a	abstract[47]	giv[47]	coref	10-15[53_47]
9-8	911-919	necrotic	abstract[47]	giv[47]	_	_
9-9	920-927	forearm	object|abstract[47]	new|giv[47]	coref	10-21
9-10	928-933	wound	abstract[47]	giv[47]	_	_
9-11	934-943	measuring	_	_	_	_
9-12	944-948	over	quantity[48]	new[48]	_	_
9-13	949-952	200	quantity[48]	new[48]	_	_
9-14	953-956	cm²	quantity[48]	new[48]	_	_
9-15	957-958	.	_	_	_	_

#Text=Within 72 hours , 100 free-range larvae cleansed over 70 % of necrosis in the wound , revealing the damaged forearm bones .
10-1	959-965	Within	_	_	_	_
10-2	966-968	72	time[49]	new[49]	_	_
10-3	969-974	hours	time[49]	new[49]	_	_
10-4	975-976	,	_	_	_	_
10-5	977-980	100	animal[50]	giv[50]	coref	17-17[98_50]
10-6	981-991	free-range	animal[50]	giv[50]	_	_
10-7	992-998	larvae	animal[50]	giv[50]	_	_
10-8	999-1007	cleansed	_	_	_	_
10-9	1008-1012	over	quantity[51]	new[51]	_	_
10-10	1013-1015	70	quantity[51]	new[51]	_	_
10-11	1016-1017	%	quantity[51]	new[51]	_	_
10-12	1018-1020	of	quantity[51]	new[51]	_	_
10-13	1021-1029	necrosis	quantity[51]|abstract	new[51]|new	coref	11-24
10-14	1030-1032	in	_	_	_	_
10-15	1033-1036	the	abstract[53]	giv[53]	coref	12-10[0_53]
10-16	1037-1042	wound	abstract[53]	giv[53]	_	_
10-17	1043-1044	,	_	_	_	_
10-18	1045-1054	revealing	_	_	_	_
10-19	1055-1058	the	object[55]	new[55]	_	_
10-20	1059-1066	damaged	object[55]	new[55]	_	_
10-21	1067-1074	forearm	object|object[55]	giv|new[55]	_	_
10-22	1075-1080	bones	object[55]	new[55]	_	_
10-23	1081-1082	.	_	_	_	_

#Text=The above observations suggest the potential use of this method in cases where wounds cover full skin-thickness , with a high risk of necrosis , or an already existing infection .
11-1	1083-1086	The	abstract[56]	new[56]	_	_
11-2	1087-1092	above	abstract[56]	new[56]	_	_
11-3	1093-1105	observations	abstract[56]	new[56]	_	_
11-4	1106-1113	suggest	_	_	_	_
11-5	1114-1117	the	abstract[57]	new[57]	_	_
11-6	1118-1127	potential	abstract[57]	new[57]	_	_
11-7	1128-1131	use	abstract[57]	new[57]	_	_
11-8	1132-1134	of	abstract[57]	new[57]	_	_
11-9	1135-1139	this	abstract[57]|abstract[58]	new[57]|new[58]	coref	12-4[66_58]
11-10	1140-1146	method	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-11	1147-1149	in	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-12	1150-1155	cases	abstract[57]|abstract[58]|abstract	new[57]|new[58]|new	_	_
11-13	1156-1161	where	_	_	_	_
11-14	1162-1168	wounds	object	new	_	_
11-15	1169-1174	cover	_	_	_	_
11-16	1175-1179	full	quantity[61]	new[61]	_	_
11-17	1180-1194	skin-thickness	quantity[61]	new[61]	_	_
11-18	1195-1196	,	_	_	_	_
11-19	1197-1201	with	_	_	_	_
11-20	1202-1203	a	abstract[62]	new[62]	_	_
11-21	1204-1208	high	abstract[62]	new[62]	_	_
11-22	1209-1213	risk	abstract[62]	new[62]	_	_
11-23	1214-1216	of	abstract[62]	new[62]	_	_
11-24	1217-1225	necrosis	abstract[62]|event	new[62]|giv	coref	21-4
11-25	1226-1227	,	_	_	_	_
11-26	1228-1230	or	_	_	_	_
11-27	1231-1233	an	abstract[64]	new[64]	_	_
11-28	1234-1241	already	abstract[64]	new[64]	_	_
11-29	1242-1250	existing	abstract[64]	new[64]	_	_
11-30	1251-1260	infection	abstract[64]	new[64]	_	_
11-31	1261-1262	.	_	_	_	_

#Text=The selection of an appropriate method for the further wound healing process is the next stage of local action .
12-1	1263-1266	The	event[65]	new[65]	coref	12-14[70_65]
12-2	1267-1276	selection	event[65]	new[65]	_	_
12-3	1277-1279	of	event[65]	new[65]	_	_
12-4	1280-1282	an	event[65]|abstract[66]	new[65]|giv[66]	_	_
12-5	1283-1294	appropriate	event[65]|abstract[66]	new[65]|giv[66]	_	_
12-6	1295-1301	method	event[65]|abstract[66]	new[65]|giv[66]	_	_
12-7	1302-1305	for	event[65]|abstract[66]	new[65]|giv[66]	_	_
12-8	1306-1309	the	event[65]|abstract[66]|abstract[69]	new[65]|giv[66]|giv[69]	coref	18-13[104_69]
12-9	1310-1317	further	event[65]|abstract[66]|abstract[69]	new[65]|giv[66]|giv[69]	_	_
12-10	1318-1323	wound	event[65]|abstract[66]|abstract|abstract[69]	new[65]|giv[66]|giv|giv[69]	coref	14-6
12-11	1324-1331	healing	event[65]|abstract[66]|event|abstract[69]	new[65]|giv[66]|giv|giv[69]	coref	22-18
12-12	1332-1339	process	event[65]|abstract[66]|abstract[69]	new[65]|giv[66]|giv[69]	_	_
12-13	1340-1342	is	_	_	_	_
12-14	1343-1346	the	event[70]	giv[70]	_	_
12-15	1347-1351	next	event[70]	giv[70]	_	_
12-16	1352-1357	stage	event[70]	giv[70]	_	_
12-17	1358-1360	of	event[70]	giv[70]	_	_
12-18	1361-1366	local	event[70]|abstract[71]	giv[70]|new[71]	_	_
12-19	1367-1373	action	event[70]|abstract[71]	giv[70]|new[71]	_	_
12-20	1374-1375	.	_	_	_	_

#Text=A maggot does not literally consume pieces of tissue , but it secretes and excretes digestive enzymes ( digestive secretions and excretions of arginase ) .
13-1	1376-1377	A	animal[72]	new[72]	ana	13-12[0_72]
13-2	1378-1384	maggot	animal[72]	new[72]	_	_
13-3	1385-1389	does	_	_	_	_
13-4	1390-1393	not	_	_	_	_
13-5	1394-1403	literally	_	_	_	_
13-6	1404-1411	consume	_	_	_	_
13-7	1412-1418	pieces	object[73]	new[73]	_	_
13-8	1419-1421	of	object[73]	new[73]	_	_
13-9	1422-1428	tissue	object[73]|object	new[73]|giv	coref	15-1[84_0]
13-10	1429-1430	,	_	_	_	_
13-11	1431-1434	but	_	_	_	_
13-12	1435-1437	it	animal	giv	coref	14-11[82_0]
13-13	1438-1446	secretes	_	_	_	_
13-14	1447-1450	and	_	_	_	_
13-15	1451-1459	excretes	_	_	_	_
13-16	1460-1469	digestive	substance[76]	new[76]	appos	13-19[77_76]
13-17	1470-1477	enzymes	substance[76]	new[76]	_	_
13-18	1478-1479	(	_	_	_	_
13-19	1480-1489	digestive	substance[77]	giv[77]	coref	17-13[97_77]
13-20	1490-1500	secretions	substance[77]	giv[77]	_	_
13-21	1501-1504	and	substance[77]	giv[77]	_	_
13-22	1505-1515	excretions	substance[77]	giv[77]	_	_
13-23	1516-1518	of	substance[77]	giv[77]	_	_
13-24	1519-1527	arginase	substance[77]|substance	giv[77]|new	coref	18-9[102_0]
13-25	1528-1529	)	_	_	_	_
13-26	1530-1531	.	_	_	_	_

#Text=Digestion begins directly in the wound bed , outside the maggot ’s body .
14-1	1532-1541	Digestion	substance	new	_	_
14-2	1542-1548	begins	_	_	_	_
14-3	1549-1557	directly	_	_	_	_
14-4	1558-1560	in	_	_	_	_
14-5	1561-1564	the	place[81]	giv[81]	coref	23-23[141_81]
14-6	1565-1570	wound	abstract|place[81]	giv|giv[81]	coref	16-19[91_0]
14-7	1571-1574	bed	place[81]	giv[81]	_	_
14-8	1575-1576	,	_	_	_	_
14-9	1577-1584	outside	_	_	_	_
14-10	1585-1588	the	object[83]	new[83]	_	_
14-11	1589-1595	maggot	animal[82]|object[83]	giv[82]|new[83]	coref	15-11[85_82]
14-12	1596-1598	’s	animal[82]|object[83]	giv[82]|new[83]	_	_
14-13	1599-1603	body	object[83]	new[83]	_	_
14-14	1604-1605	.	_	_	_	_

#Text=Dead tissue is liquefied and can be easily absorbed by the maggot .
15-1	1606-1610	Dead	object[84]	giv[84]	coref	18-7[0_84]
15-2	1611-1617	tissue	object[84]	giv[84]	_	_
15-3	1618-1620	is	_	_	_	_
15-4	1621-1630	liquefied	_	_	_	_
15-5	1631-1634	and	_	_	_	_
15-6	1635-1638	can	_	_	_	_
15-7	1639-1641	be	_	_	_	_
15-8	1642-1648	easily	_	_	_	_
15-9	1649-1657	absorbed	_	_	_	_
15-10	1658-1660	by	_	_	_	_
15-11	1661-1664	the	animal[85]	giv[85]	_	_
15-12	1665-1671	maggot	animal[85]	giv[85]	_	_
15-13	1672-1673	.	_	_	_	_

#Text=This phenomenon can be easily observed during therapy because of the increase in the amount of exudate from the wound and its specific odor .
16-1	1674-1678	This	abstract[86]	new[86]	_	_
16-2	1679-1689	phenomenon	abstract[86]	new[86]	_	_
16-3	1690-1693	can	_	_	_	_
16-4	1694-1696	be	_	_	_	_
16-5	1697-1703	easily	_	_	_	_
16-6	1704-1712	observed	_	_	_	_
16-7	1713-1719	during	_	_	_	_
16-8	1720-1727	therapy	event[87]	new[87]	coref	36-4[251_87]
16-9	1728-1735	because	event[87]	new[87]	_	_
16-10	1736-1738	of	event[87]	new[87]	_	_
16-11	1739-1742	the	event[87]|abstract[88]	new[87]|new[88]	_	_
16-12	1743-1751	increase	event[87]|abstract[88]	new[87]|new[88]	_	_
16-13	1752-1754	in	event[87]|abstract[88]	new[87]|new[88]	_	_
16-14	1755-1758	the	event[87]|abstract[88]|quantity[89]	new[87]|new[88]|new[89]	_	_
16-15	1759-1765	amount	event[87]|abstract[88]|quantity[89]	new[87]|new[88]|new[89]	_	_
16-16	1766-1768	of	event[87]|abstract[88]|quantity[89]	new[87]|new[88]|new[89]	_	_
16-17	1769-1776	exudate	event[87]|abstract[88]|quantity[89]|abstract	new[87]|new[88]|new[89]|new	coref	36-19
16-18	1777-1781	from	event[87]|abstract[88]|quantity[89]	new[87]|new[88]|new[89]	_	_
16-19	1782-1785	the	event[87]|abstract[88]|quantity[89]|abstract[91]	new[87]|new[88]|new[89]|giv[91]	coref	20-7[113_91]
16-20	1786-1791	wound	event[87]|abstract[88]|quantity[89]|abstract[91]	new[87]|new[88]|new[89]|giv[91]	_	_
16-21	1792-1795	and	event[87]|abstract[88]|quantity[89]	new[87]|new[88]|new[89]	_	_
16-22	1796-1799	its	event[87]|abstract[88]|quantity[89]|abstract[92]	new[87]|new[88]|new[89]|new[92]	_	_
16-23	1800-1808	specific	event[87]|abstract[88]|quantity[89]|abstract[92]	new[87]|new[88]|new[89]|new[92]	_	_
16-24	1809-1813	odor	event[87]|abstract[88]|quantity[89]|abstract[92]	new[87]|new[88]|new[89]|new[92]	_	_
16-25	1814-1815	.	_	_	_	_

#Text=Hobson was the first scientist to systematically present the proteolytic effects of digestive enzymes produced by the larvae of Lucilia sericata .
17-1	1816-1822	Hobson	person	new	coref	17-3[94_0]
17-2	1823-1826	was	_	_	_	_
17-3	1827-1830	the	person[94]	giv[94]	_	_
17-4	1831-1836	first	person[94]	giv[94]	_	_
17-5	1837-1846	scientist	person[94]	giv[94]	_	_
17-6	1847-1849	to	_	_	_	_
17-7	1850-1864	systematically	_	_	_	_
17-8	1865-1872	present	_	_	_	_
17-9	1873-1876	the	abstract[95]	new[95]	_	_
17-10	1877-1888	proteolytic	abstract[95]	new[95]	_	_
17-11	1889-1896	effects	abstract[95]	new[95]	_	_
17-12	1897-1899	of	abstract[95]	new[95]	_	_
17-13	1900-1909	digestive	abstract[95]|abstract|substance[97]	new[95]|new|giv[97]	coref	19-1[105_97]
17-14	1910-1917	enzymes	abstract[95]|substance[97]	new[95]|giv[97]	_	_
17-15	1918-1926	produced	_	_	_	_
17-16	1927-1929	by	_	_	_	_
17-17	1930-1933	the	animal[98]	giv[98]	coref	25-23[165_98]
17-18	1934-1940	larvae	animal[98]	giv[98]	_	_
17-19	1941-1943	of	animal[98]	giv[98]	_	_
17-20	1944-1951	Lucilia	animal[98]	giv[98]	_	_
17-21	1952-1960	sericata	animal[98]	giv[98]	_	_
17-22	1961-1962	.	_	_	_	_

#Text=The movements of maggots , scratching tissue and secreting arginase , facilitate the debridement process .
18-1	1963-1966	The	abstract[99]	new[99]	_	_
18-2	1967-1976	movements	abstract[99]	new[99]	_	_
18-3	1977-1979	of	abstract[99]	new[99]	_	_
18-4	1980-1987	maggots	abstract[99]|animal	new[99]|new	coref	20-28[118_0]
18-5	1988-1989	,	abstract[99]	new[99]	_	_
18-6	1990-2000	scratching	abstract[99]	new[99]	_	_
18-7	2001-2007	tissue	abstract[99]|object	new[99]|giv	coref	20-13[115_0]
18-8	2008-2011	and	abstract[99]	new[99]	_	_
18-9	2012-2021	secreting	abstract[99]|substance[102]	new[99]|giv[102]	_	_
18-10	2022-2030	arginase	abstract[99]|substance[102]	new[99]|giv[102]	_	_
18-11	2031-2032	,	_	_	_	_
18-12	2033-2043	facilitate	_	_	_	_
18-13	2044-2047	the	abstract[104]	giv[104]	coref	21-11[124_104]
18-14	2048-2059	debridement	abstract|abstract[104]	giv|giv[104]	coref	31-2
18-15	2060-2067	process	abstract[104]	giv[104]	_	_
18-16	2068-2069	.	_	_	_	_

#Text=Other enzymes released include leucine aminopeptidase , collagenase and chymotrypsin-like proteases .
19-1	2070-2075	Other	substance[105]	giv[105]	coref	20-1[111_105]
19-2	2076-2083	enzymes	substance[105]	giv[105]	_	_
19-3	2084-2092	released	_	_	_	_
19-4	2093-2100	include	_	_	_	_
19-5	2101-2108	leucine	substance|substance[107]	new|new[107]	_	_
19-6	2109-2123	aminopeptidase	substance[107]	new[107]	_	_
19-7	2124-2125	,	_	_	_	_
19-8	2126-2137	collagenase	object	new	coref	25-1
19-9	2138-2141	and	_	_	_	_
19-10	2142-2159	chymotrypsin-like	abstract|object[110]	new|new[110]	_	_
19-11	2160-2169	proteases	object[110]	new[110]	_	_
19-12	2170-2171	.	_	_	_	_

#Text=These enzymes have various functions in the wound ; they mainly transform dead tissue into liquid , which is either exuded from the wound or consumed by the maggots .
20-1	2172-2177	These	substance[111]	giv[111]	coref	24-17[152_111]
20-2	2178-2185	enzymes	substance[111]	giv[111]	_	_
20-3	2186-2190	have	_	_	_	_
20-4	2191-2198	various	abstract[112]	new[112]	ana	20-10[0_112]
20-5	2199-2208	functions	abstract[112]	new[112]	_	_
20-6	2209-2211	in	abstract[112]	new[112]	_	_
20-7	2212-2215	the	abstract[112]|abstract[113]	new[112]|giv[113]	coref	20-23[117_113]
20-8	2216-2221	wound	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
20-9	2222-2223	;	_	_	_	_
20-10	2224-2228	they	abstract	giv	_	_
20-11	2229-2235	mainly	_	_	_	_
20-12	2236-2245	transform	_	_	_	_
20-13	2246-2250	dead	object[115]	giv[115]	coref	27-8[0_115]
20-14	2251-2257	tissue	object[115]	giv[115]	_	_
20-15	2258-2262	into	_	_	_	_
20-16	2263-2269	liquid	substance	new	_	_
20-17	2270-2271	,	_	_	_	_
20-18	2272-2277	which	_	_	_	_
20-19	2278-2280	is	_	_	_	_
20-20	2281-2287	either	_	_	_	_
20-21	2288-2294	exuded	_	_	_	_
20-22	2295-2299	from	_	_	_	_
20-23	2300-2303	the	abstract[117]	giv[117]	coref	23-20[0_117]
20-24	2304-2309	wound	abstract[117]	giv[117]	_	_
20-25	2310-2312	or	_	_	_	_
20-26	2313-2321	consumed	_	_	_	_
20-27	2322-2324	by	_	_	_	_
20-28	2325-2328	the	animal[118]	giv[118]	_	_
20-29	2329-2336	maggots	animal[118]	giv[118]	_	_
20-30	2337-2338	.	_	_	_	_

#Text=The evacuation of necrosis and reduction in bacterial contamination promotes the regeneration process .
21-1	2339-2342	The	event[119]	new[119]	_	_
21-2	2343-2353	evacuation	event[119]	new[119]	_	_
21-3	2354-2356	of	event[119]	new[119]	_	_
21-4	2357-2365	necrosis	event[119]|abstract	new[119]|giv	coref	26-2
21-5	2366-2369	and	event[119]	new[119]	_	_
21-6	2370-2379	reduction	event[119]|abstract[121]	new[119]|new[121]	_	_
21-7	2380-2382	in	event[119]|abstract[121]	new[119]|new[121]	_	_
21-8	2383-2392	bacterial	event[119]|abstract[121]|substance[122]	new[119]|new[121]|new[122]	_	_
21-9	2393-2406	contamination	event[119]|abstract[121]|substance[122]	new[119]|new[121]|new[122]	_	_
21-10	2407-2415	promotes	_	_	_	_
21-11	2416-2419	the	abstract[124]	giv[124]	coref	22-17[130_124]
21-12	2420-2432	regeneration	abstract|abstract[124]	new|giv[124]	coref	26-31[174_0]
21-13	2433-2440	process	abstract[124]	giv[124]	_	_
21-14	2441-2442	.	_	_	_	_

#Text=The authors of numerous recently published papers have noted chemical substances that influence the promotion of the healing process .
22-1	2443-2446	The	person[125]	new[125]	_	_
22-2	2447-2454	authors	person[125]	new[125]	_	_
22-3	2455-2457	of	person[125]	new[125]	_	_
22-4	2458-2466	numerous	person[125]|object[126]	new[125]|new[126]	_	_
22-5	2467-2475	recently	person[125]|object[126]	new[125]|new[126]	_	_
22-6	2476-2485	published	person[125]|object[126]	new[125]|new[126]	_	_
22-7	2486-2492	papers	person[125]|object[126]	new[125]|new[126]	_	_
22-8	2493-2497	have	_	_	_	_
22-9	2498-2503	noted	_	_	_	_
22-10	2504-2512	chemical	substance[127]	new[127]	_	_
22-11	2513-2523	substances	substance[127]	new[127]	_	_
22-12	2524-2528	that	_	_	_	_
22-13	2529-2538	influence	_	_	_	_
22-14	2539-2542	the	abstract[128]	new[128]	_	_
22-15	2543-2552	promotion	abstract[128]	new[128]	_	_
22-16	2553-2555	of	abstract[128]	new[128]	_	_
22-17	2556-2559	the	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
22-18	2560-2567	healing	abstract[128]|object|abstract[130]	new[128]|giv|giv[130]	coref	23-32[144_0]
22-19	2568-2575	process	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
22-20	2576-2577	.	_	_	_	_

#Text=The migration of resident epidermal keratinocytes and dermal cells , including fibroblasts and dermal microvascular cells , from the wound margins into the wound bed , is a crucial step in wound healing .
23-1	2578-2581	The	abstract[131]	new[131]	coref	23-28[142_131]
23-2	2582-2591	migration	abstract[131]	new[131]	_	_
23-3	2592-2594	of	abstract[131]	new[131]	_	_
23-4	2595-2603	resident	abstract[131]|object[132]	new[131]|new[132]	_	_
23-5	2604-2613	epidermal	abstract[131]|object[132]	new[131]|new[132]	_	_
23-6	2614-2627	keratinocytes	abstract[131]|object[132]	new[131]|new[132]	_	_
23-7	2628-2631	and	abstract[131]	new[131]	_	_
23-8	2632-2638	dermal	abstract[131]|animal|object[134]	new[131]|new|new[134]	coref	23-14
23-9	2639-2644	cells	abstract[131]|object[134]	new[131]|new[134]	_	_
23-10	2645-2646	,	abstract[131]	new[131]	_	_
23-11	2647-2656	including	abstract[131]	new[131]	_	_
23-12	2657-2668	fibroblasts	abstract[131]|object	new[131]|new	_	_
23-13	2669-2672	and	abstract[131]	new[131]	_	_
23-14	2673-2679	dermal	abstract[131]|animal|object[137]	new[131]|giv|new[137]	coref	24-36[157_137]
23-15	2680-2693	microvascular	abstract[131]|object[137]	new[131]|new[137]	_	_
23-16	2694-2699	cells	abstract[131]|object[137]	new[131]|new[137]	_	_
23-17	2700-2701	,	abstract[131]	new[131]	_	_
23-18	2702-2706	from	abstract[131]	new[131]	_	_
23-19	2707-2710	the	abstract[131]|place[139]	new[131]|new[139]	_	_
23-20	2711-2716	wound	abstract[131]|abstract|place[139]	new[131]|giv|new[139]	coref	23-24
23-21	2717-2724	margins	abstract[131]|place[139]	new[131]|new[139]	_	_
23-22	2725-2729	into	abstract[131]|place[139]	new[131]|new[139]	_	_
23-23	2730-2733	the	abstract[131]|place[139]|place[141]	new[131]|new[139]|giv[141]	_	_
23-24	2734-2739	wound	abstract[131]|place[139]|abstract|place[141]	new[131]|new[139]|giv|giv[141]	coref	23-32
23-25	2740-2743	bed	abstract[131]|place[139]|place[141]	new[131]|new[139]|giv[141]	_	_
23-26	2744-2745	,	_	_	_	_
23-27	2746-2748	is	_	_	_	_
23-28	2749-2750	a	abstract[142]	giv[142]	ana	24-21[0_142]
23-29	2751-2758	crucial	abstract[142]	giv[142]	_	_
23-30	2759-2763	step	abstract[142]	giv[142]	_	_
23-31	2764-2766	in	abstract[142]	giv[142]	_	_
23-32	2767-2772	wound	abstract[142]|abstract|object[144]	giv[142]|giv|giv[144]	coref|coref	26-11[0_144]|31-4[218_0]
23-33	2773-2780	healing	abstract[142]|object[144]	giv[142]|giv[144]	_	_
23-34	2781-2782	.	_	_	_	_

#Text=Amino acids , such as L-histidine , 3-guanidinopropionic acid and L-valinol , have been identified in larva secretions , and it has been demonstrated in vitro that these isolated components specifically increase the proliferation of human endothelial cells .
24-1	2783-2788	Amino	object|substance[146]	new|new[146]	_	_
24-2	2789-2794	acids	substance[146]	new[146]	_	_
24-3	2795-2796	,	substance[146]	new[146]	_	_
24-4	2797-2801	such	substance[146]	new[146]	_	_
24-5	2802-2804	as	substance[146]	new[146]	_	_
24-6	2805-2816	L-histidine	substance[146]|substance	new[146]|new	_	_
24-7	2817-2818	,	substance[146]	new[146]	_	_
24-8	2819-2839	3-guanidinopropionic	substance[146]|abstract|substance[149]	new[146]|new|new[149]	_	_
24-9	2840-2844	acid	substance[146]|substance[149]	new[146]|new[149]	_	_
24-10	2845-2848	and	substance[146]	new[146]	_	_
24-11	2849-2858	L-valinol	substance[146]|substance	new[146]|new	_	_
24-12	2859-2860	,	_	_	_	_
24-13	2861-2865	have	_	_	_	_
24-14	2866-2870	been	_	_	_	_
24-15	2871-2881	identified	_	_	_	_
24-16	2882-2884	in	_	_	_	_
24-17	2885-2890	larva	animal|substance[152]	new|giv[152]	coref	25-19[164_152]
24-18	2891-2901	secretions	substance[152]	giv[152]	_	_
24-19	2902-2903	,	_	_	_	_
24-20	2904-2907	and	_	_	_	_
24-21	2908-2910	it	abstract	giv	_	_
24-22	2911-2914	has	_	_	_	_
24-23	2915-2919	been	_	_	_	_
24-24	2920-2932	demonstrated	_	_	_	_
24-25	2933-2935	in	_	_	_	_
24-26	2936-2941	vitro	_	_	_	_
24-27	2942-2946	that	_	_	_	_
24-28	2947-2952	these	abstract[154]	new[154]	coref	25-13[163_154]
24-29	2953-2961	isolated	abstract[154]	new[154]	_	_
24-30	2962-2972	components	abstract[154]	new[154]	_	_
24-31	2973-2985	specifically	_	_	_	_
24-32	2986-2994	increase	_	_	_	_
24-33	2995-2998	the	event[155]	new[155]	_	_
24-34	2999-3012	proliferation	event[155]	new[155]	_	_
24-35	3013-3015	of	event[155]	new[155]	_	_
24-36	3016-3021	human	event[155]|object[157]	new[155]|giv[157]	_	_
24-37	3022-3033	endothelial	event[155]|object|object[157]	new[155]|new|giv[157]	_	_
24-38	3034-3039	cells	event[155]|object[157]	new[155]|giv[157]	_	_
24-39	3040-3041	.	_	_	_	_

#Text=Collagenase speeds up the process of proteolysis by decomposing the material into smaller components , digested later by other enzymes secreted by the larvae .
25-1	3042-3053	Collagenase	substance|abstract[159]	giv|new[159]	appos	25-4[160_159]
25-2	3054-3060	speeds	abstract[159]	new[159]	_	_
25-3	3061-3063	up	abstract[159]	new[159]	_	_
25-4	3064-3067	the	abstract[160]	giv[160]	_	_
25-5	3068-3075	process	abstract[160]	giv[160]	_	_
25-6	3076-3078	of	abstract[160]	giv[160]	_	_
25-7	3079-3090	proteolysis	abstract[160]|substance	giv[160]|new	_	_
25-8	3091-3093	by	_	_	_	_
25-9	3094-3105	decomposing	_	_	_	_
25-10	3106-3109	the	substance[162]	new[162]	_	_
25-11	3110-3118	material	substance[162]	new[162]	_	_
25-12	3119-3123	into	_	_	_	_
25-13	3124-3131	smaller	abstract[163]	giv[163]	_	_
25-14	3132-3142	components	abstract[163]	giv[163]	_	_
25-15	3143-3144	,	_	_	_	_
25-16	3145-3153	digested	_	_	_	_
25-17	3154-3159	later	_	_	_	_
25-18	3160-3162	by	_	_	_	_
25-19	3163-3168	other	substance[164]	giv[164]	coref	33-12[229_164]
25-20	3169-3176	enzymes	substance[164]	giv[164]	_	_
25-21	3177-3185	secreted	_	_	_	_
25-22	3186-3188	by	_	_	_	_
25-23	3189-3192	the	animal[165]	giv[165]	coref	28-9[0_165]
25-24	3193-3199	larvae	animal[165]	giv[165]	_	_
25-25	3200-3201	.	_	_	_	_

#Text=Once necrosis is effectively removed , the consecutive stages of healing are facilitated by the increased phagocytic activity of leukocytes and higher oxygen pressure , resulting in optimum conditions for the regeneration of damaged tissues .
26-1	3202-3206	Once	_	_	_	_
26-2	3207-3215	necrosis	event	giv	_	_
26-3	3216-3218	is	_	_	_	_
26-4	3219-3230	effectively	_	_	_	_
26-5	3231-3238	removed	_	_	_	_
26-6	3239-3240	,	_	_	_	_
26-7	3241-3244	the	event[167]	new[167]	_	_
26-8	3245-3256	consecutive	event[167]	new[167]	_	_
26-9	3257-3263	stages	event[167]	new[167]	_	_
26-10	3264-3266	of	event[167]	new[167]	_	_
26-11	3267-3274	healing	event[167]|object	new[167]|giv	_	_
26-12	3275-3278	are	_	_	_	_
26-13	3279-3290	facilitated	_	_	_	_
26-14	3291-3293	by	_	_	_	_
26-15	3294-3297	the	abstract[169]	new[169]	_	_
26-16	3298-3307	increased	abstract[169]	new[169]	_	_
26-17	3308-3318	phagocytic	abstract[169]	new[169]	_	_
26-18	3319-3327	activity	abstract[169]	new[169]	_	_
26-19	3328-3330	of	abstract[169]	new[169]	_	_
26-20	3331-3341	leukocytes	abstract[169]|substance	new[169]|new	_	_
26-21	3342-3345	and	abstract[169]	new[169]	_	_
26-22	3346-3352	higher	abstract[169]|abstract[172]	new[169]|new[172]	coref	36-5[0_172]
26-23	3353-3359	oxygen	abstract[169]|substance|abstract[172]	new[169]|new|new[172]	_	_
26-24	3360-3368	pressure	abstract[169]|abstract[172]	new[169]|new[172]	_	_
26-25	3369-3370	,	_	_	_	_
26-26	3371-3380	resulting	_	_	_	_
26-27	3381-3383	in	_	_	_	_
26-28	3384-3391	optimum	abstract[173]	new[173]	_	_
26-29	3392-3402	conditions	abstract[173]	new[173]	_	_
26-30	3403-3406	for	abstract[173]	new[173]	_	_
26-31	3407-3410	the	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-32	3411-3423	regeneration	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-33	3424-3426	of	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-34	3427-3434	damaged	abstract[173]|abstract[174]|object[175]	new[173]|giv[174]|new[175]	_	_
26-35	3435-3442	tissues	abstract[173]|abstract[174]|object[175]	new[173]|giv[174]|new[175]	_	_
26-36	3443-3444	.	_	_	_	_

#Text=Proteolytic digestion is the initial act of tissue repair , leading to hemostasis , thrombosis , inflammatory cell activation and the reconstruction of tissue .
27-1	3445-3456	Proteolytic	abstract[176]	new[176]	coref	27-4[177_176]
27-2	3457-3466	digestion	abstract[176]	new[176]	_	_
27-3	3467-3469	is	_	_	_	_
27-4	3470-3473	the	abstract[177]	giv[177]	_	_
27-5	3474-3481	initial	abstract[177]	giv[177]	_	_
27-6	3482-3485	act	abstract[177]	giv[177]	_	_
27-7	3486-3488	of	abstract[177]	giv[177]	_	_
27-8	3489-3495	tissue	abstract[177]|object|abstract[179]	giv[177]|giv|new[179]	coref	27-24
27-9	3496-3502	repair	abstract[177]|abstract[179]	giv[177]|new[179]	_	_
27-10	3503-3504	,	_	_	_	_
27-11	3505-3512	leading	_	_	_	_
27-12	3513-3515	to	_	_	_	_
27-13	3516-3526	hemostasis	substance	new	_	_
27-14	3527-3528	,	_	_	_	_
27-15	3529-3539	thrombosis	event	new	_	_
27-16	3540-3541	,	_	_	_	_
27-17	3542-3554	inflammatory	event[183]	new[183]	_	_
27-18	3555-3559	cell	place|event[183]	new|new[183]	_	_
27-19	3560-3570	activation	event[183]	new[183]	_	_
27-20	3571-3574	and	_	_	_	_
27-21	3575-3578	the	event[184]	new[184]	_	_
27-22	3579-3593	reconstruction	event[184]	new[184]	_	_
27-23	3594-3596	of	event[184]	new[184]	_	_
27-24	3597-3603	tissue	event[184]|object	new[184]|giv	coref	33-1[227_0]
27-25	3604-3605	.	_	_	_	_

#Text=Several studies suggest that the beneficial effect of larvae may be due to their ability to reduce pro-inflammatory factors .
28-1	3606-3613	Several	abstract[186]	new[186]	_	_
28-2	3614-3621	studies	abstract[186]	new[186]	_	_
28-3	3622-3629	suggest	_	_	_	_
28-4	3630-3634	that	_	_	_	_
28-5	3635-3638	the	abstract[187]	new[187]	_	_
28-6	3639-3649	beneficial	abstract[187]	new[187]	_	_
28-7	3650-3656	effect	abstract[187]	new[187]	_	_
28-8	3657-3659	of	abstract[187]	new[187]	_	_
28-9	3660-3666	larvae	abstract[187]|animal	new[187]|giv	ana	28-14
28-10	3667-3670	may	_	_	_	_
28-11	3671-3673	be	_	_	_	_
28-12	3674-3677	due	_	_	_	_
28-13	3678-3680	to	_	_	_	_
28-14	3681-3686	their	animal|abstract[190]	giv|new[190]	_	_
28-15	3687-3694	ability	abstract[190]	new[190]	_	_
28-16	3695-3697	to	_	_	_	_
28-17	3698-3704	reduce	_	_	_	_
28-18	3705-3721	pro-inflammatory	abstract[191]	new[191]	coref	34-7[234_191]
28-19	3722-3729	factors	abstract[191]	new[191]	_	_
28-20	3730-3731	.	_	_	_	_

#Text=The work of Pecivova et al. studied the effect of the Lucilia sericata salivary gland extract on opsonized neutrophils , stimulated with zymogen and unstimulated neutrophils .
29-1	3732-3735	The	abstract[192]	new[192]	_	_
29-2	3736-3740	work	abstract[192]	new[192]	_	_
29-3	3741-3743	of	abstract[192]	new[192]	_	_
29-4	3744-3752	Pecivova	abstract[192]|person	new[192]|new	_	_
29-5	3753-3755	et	abstract[192]	new[192]	_	_
29-6	3756-3759	al.	abstract[192]	new[192]	_	_
29-7	3760-3767	studied	_	_	_	_
29-8	3768-3771	the	abstract[194]	new[194]	coref	30-5[203_194]
29-9	3772-3778	effect	abstract[194]	new[194]	_	_
29-10	3779-3781	of	abstract[194]	new[194]	_	_
29-11	3782-3785	the	abstract[194]	new[194]	_	_
29-12	3786-3793	Lucilia	abstract[194]	new[194]	_	_
29-13	3794-3802	sericata	abstract[194]	new[194]	_	_
29-14	3803-3811	salivary	abstract[194]|substance[196]	new[194]|new[196]	coref	30-1[202_196]
29-15	3812-3817	gland	abstract[194]|substance|substance[196]	new[194]|new|new[196]	coref	30-2
29-16	3818-3825	extract	abstract[194]|substance[196]	new[194]|new[196]	_	_
29-17	3826-3828	on	abstract[194]|substance[196]	new[194]|new[196]	_	_
29-18	3829-3838	opsonized	abstract[194]|substance[196]|object[197]	new[194]|new[196]|new[197]	coref	29-25[199_197]
29-19	3839-3850	neutrophils	abstract[194]|substance[196]|object[197]	new[194]|new[196]|new[197]	_	_
29-20	3851-3852	,	_	_	_	_
29-21	3853-3863	stimulated	_	_	_	_
29-22	3864-3868	with	_	_	_	_
29-23	3869-3876	zymogen	substance	new	_	_
29-24	3877-3880	and	_	_	_	_
29-25	3881-3893	unstimulated	object[199]	giv[199]	coref	30-14[209_199]
29-26	3894-3905	neutrophils	object[199]	giv[199]	_	_
29-27	3906-3907	.	_	_	_	_

#Text=Salivary gland extract had no effect on superoxide production and myeloperoxidase release from unstimulated neutrophils , but significantly reduced both peroxide production and MPO secretion levels in zsonogen-stimulated opsonized neutrophils .
30-1	3908-3916	Salivary	substance|substance[202]	new|giv[202]	_	_
30-2	3917-3922	gland	substance|substance[202]	giv|giv[202]	_	_
30-3	3923-3930	extract	substance[202]	giv[202]	_	_
30-4	3931-3934	had	_	_	_	_
30-5	3935-3937	no	abstract[203]	giv[203]	_	_
30-6	3938-3944	effect	abstract[203]	giv[203]	_	_
30-7	3945-3947	on	abstract[203]	giv[203]	_	_
30-8	3948-3958	superoxide	abstract[203]|substance|abstract[205]|abstract[206]	giv[203]|new|new[205]|new[206]	coref|coref	30-20[211_205]|30-20[212_206]
30-9	3959-3969	production	abstract[203]|abstract[205]|abstract[206]	giv[203]|new[205]|new[206]	_	_
30-10	3970-3973	and	abstract[203]|abstract[206]	giv[203]|new[206]	_	_
30-11	3974-3989	myeloperoxidase	abstract[203]|abstract[206]|abstract|event[208]	giv[203]|new[206]|new|new[208]	_	_
30-12	3990-3997	release	abstract[203]|abstract[206]|event[208]	giv[203]|new[206]|new[208]	_	_
30-13	3998-4002	from	abstract[203]|abstract[206]|event[208]	giv[203]|new[206]|new[208]	_	_
30-14	4003-4015	unstimulated	abstract[203]|abstract[206]|event[208]|object[209]	giv[203]|new[206]|new[208]|giv[209]	coref	30-28[216_209]
30-15	4016-4027	neutrophils	abstract[203]|abstract[206]|event[208]|object[209]	giv[203]|new[206]|new[208]|giv[209]	_	_
30-16	4028-4029	,	_	_	_	_
30-17	4030-4033	but	_	_	_	_
30-18	4034-4047	significantly	_	_	_	_
30-19	4048-4055	reduced	_	_	_	_
30-20	4056-4060	both	abstract[211]|abstract[212]	giv[211]|giv[212]	_	_
30-21	4061-4069	peroxide	substance|abstract[211]|abstract[212]	new|giv[211]|giv[212]	_	_
30-22	4070-4080	production	abstract[211]|abstract[212]	giv[211]|giv[212]	_	_
30-23	4081-4084	and	abstract[212]	giv[212]	_	_
30-24	4085-4088	MPO	abstract[212]|substance|abstract[215]	giv[212]|new|new[215]	_	_
30-25	4089-4098	secretion	abstract[212]|abstract|abstract[215]	giv[212]|new|new[215]	_	_
30-26	4099-4105	levels	abstract[212]|abstract[215]	giv[212]|new[215]	_	_
30-27	4106-4108	in	abstract[212]|abstract[215]	giv[212]|new[215]	_	_
30-28	4109-4128	zsonogen-stimulated	abstract[212]|abstract[215]|object[216]	giv[212]|new[215]|giv[216]	_	_
30-29	4129-4138	opsonized	abstract[212]|abstract[215]|object[216]	giv[212]|new[215]|giv[216]	_	_
30-30	4139-4150	neutrophils	abstract[212]|abstract[215]|object[216]	giv[212]|new[215]|giv[216]	_	_
30-31	4151-4152	.	_	_	_	_

#Text=Following debridement , the wound may be appropriately assessed .
31-1	4153-4162	Following	_	_	_	_
31-2	4163-4174	debridement	event	giv	_	_
31-3	4175-4176	,	_	_	_	_
31-4	4177-4180	the	abstract[218]	giv[218]	coref	32-13[0_218]
31-5	4181-4186	wound	abstract[218]	giv[218]	_	_
31-6	4187-4190	may	_	_	_	_
31-7	4191-4193	be	_	_	_	_
31-8	4194-4207	appropriately	_	_	_	_
31-9	4208-4216	assessed	_	_	_	_
31-10	4217-4218	.	_	_	_	_

#Text=Consequently , it is also possible to introduce other methods that promote wound closure , or to perform a skin transplant .
32-1	4219-4231	Consequently	_	_	_	_
32-2	4232-4233	,	_	_	_	_
32-3	4234-4236	it	abstract	new	cata	32-3[0_220]
32-4	4237-4239	is	_	_	_	_
32-5	4240-4244	also	_	_	_	_
32-6	4245-4253	possible	_	_	_	_
32-7	4254-4256	to	abstract[220]	new[220]	_	_
32-8	4257-4266	introduce	abstract[220]	new[220]	_	_
32-9	4267-4272	other	abstract[220]|abstract[221]	new[220]|new[221]	_	_
32-10	4273-4280	methods	abstract[220]|abstract[221]	new[220]|new[221]	_	_
32-11	4281-4285	that	_	_	_	_
32-12	4286-4293	promote	_	_	_	_
32-13	4294-4299	wound	abstract|event[223]	giv|new[223]	coref	33-5[228_0]
32-14	4300-4307	closure	event[223]	new[223]	_	_
32-15	4308-4309	,	_	_	_	_
32-16	4310-4312	or	_	_	_	_
32-17	4313-4315	to	_	_	_	_
32-18	4316-4323	perform	_	_	_	_
32-19	4324-4325	a	event[225]	new[225]	_	_
32-20	4326-4330	skin	object|event[225]	new|new[225]	_	_
32-21	4331-4341	transplant	event[225]	new[225]	_	_
32-22	4342-4343	.	_	_	_	_

#Text=The granulation tissue in the wound , debrided and stimulated by larval secretions , should be dressed as soon as possible with the chosen method of local treatment .
33-1	4344-4347	The	object[227]	giv[227]	coref	34-14[0_227]
33-2	4348-4359	granulation	abstract|object[227]	new|giv[227]	_	_
33-3	4360-4366	tissue	object[227]	giv[227]	_	_
33-4	4367-4369	in	object[227]	giv[227]	_	_
33-5	4370-4373	the	object[227]|abstract[228]	giv[227]|giv[228]	coref	34-19[0_228]
33-6	4374-4379	wound	object[227]|abstract[228]	giv[227]|giv[228]	_	_
33-7	4380-4381	,	_	_	_	_
33-8	4382-4390	debrided	_	_	_	_
33-9	4391-4394	and	_	_	_	_
33-10	4395-4405	stimulated	_	_	_	_
33-11	4406-4408	by	_	_	_	_
33-12	4409-4415	larval	substance[229]	giv[229]	_	_
33-13	4416-4426	secretions	substance[229]	giv[229]	_	_
33-14	4427-4428	,	_	_	_	_
33-15	4429-4435	should	_	_	_	_
33-16	4436-4438	be	_	_	_	_
33-17	4439-4446	dressed	_	_	_	_
33-18	4447-4449	as	_	_	_	_
33-19	4450-4454	soon	_	_	_	_
33-20	4455-4457	as	_	_	_	_
33-21	4458-4466	possible	_	_	_	_
33-22	4467-4471	with	_	_	_	_
33-23	4472-4475	the	abstract[230]	new[230]	coref	34-4[0_230]
33-24	4476-4482	chosen	abstract[230]	new[230]	_	_
33-25	4483-4489	method	abstract[230]	new[230]	_	_
33-26	4490-4492	of	abstract[230]	new[230]	_	_
33-27	4493-4498	local	abstract[230]|abstract[231]	new[230]|new[231]	_	_
33-28	4499-4508	treatment	abstract[230]|abstract[231]	new[230]|new[231]	_	_
33-29	4509-4510	.	_	_	_	_

#Text=The choice of method depends on several factors , such as level of tissue destruction , area , wound etiopathogenesis , and general condition of the patient .
34-1	4511-4514	The	abstract[232]	new[232]	_	_
34-2	4515-4521	choice	abstract[232]	new[232]	_	_
34-3	4522-4524	of	abstract[232]	new[232]	_	_
34-4	4525-4531	method	abstract[232]|abstract	new[232]|giv	_	_
34-5	4532-4539	depends	_	_	_	_
34-6	4540-4542	on	_	_	_	_
34-7	4543-4550	several	abstract[234]	giv[234]	_	_
34-8	4551-4558	factors	abstract[234]	giv[234]	_	_
34-9	4559-4560	,	abstract[234]	giv[234]	_	_
34-10	4561-4565	such	abstract[234]	giv[234]	_	_
34-11	4566-4568	as	abstract[234]	giv[234]	_	_
34-12	4569-4574	level	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-13	4575-4577	of	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-14	4578-4584	tissue	abstract[234]|abstract[235]|object|event[237]	giv[234]|new[235]|giv|new[237]	coref	37-17[263_0]
34-15	4585-4596	destruction	abstract[234]|abstract[235]|event[237]	giv[234]|new[235]|new[237]	_	_
34-16	4597-4598	,	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-17	4599-4603	area	abstract[234]|abstract[235]|abstract	giv[234]|new[235]|new	_	_
34-18	4604-4605	,	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-19	4606-4611	wound	abstract[234]|abstract[235]|abstract|abstract[240]	giv[234]|new[235]|giv|new[240]	coref	36-6
34-20	4612-4628	etiopathogenesis	abstract[234]|abstract[235]|abstract[240]	giv[234]|new[235]|new[240]	_	_
34-21	4629-4630	,	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-22	4631-4634	and	abstract[234]|abstract[235]	giv[234]|new[235]	_	_
34-23	4635-4642	general	abstract[234]|abstract[235]|abstract[241]	giv[234]|new[235]|new[241]	coref	37-27[266_241]
34-24	4643-4652	condition	abstract[234]|abstract[235]|abstract[241]	giv[234]|new[235]|new[241]	_	_
34-25	4653-4655	of	abstract[234]|abstract[235]|abstract[241]	giv[234]|new[235]|new[241]	_	_
34-26	4656-4659	the	abstract[234]|abstract[235]|abstract[241]|person[242]	giv[234]|new[235]|new[241]|new[242]	coref	37-28[265_242]
34-27	4660-4667	patient	abstract[234]|abstract[235]|abstract[241]|person[242]	giv[234]|new[235]|new[241]|new[242]	_	_
34-28	4668-4669	.	_	_	_	_

#Text=Wound management criteria should be carefully implemented based on the TIME concept .
35-1	4670-4675	Wound	person|abstract[245]	new|new[245]	_	_
35-2	4676-4686	management	organization|abstract[245]	new|new[245]	_	_
35-3	4687-4695	criteria	abstract[245]	new[245]	_	_
35-4	4696-4702	should	_	_	_	_
35-5	4703-4705	be	_	_	_	_
35-6	4706-4715	carefully	_	_	_	_
35-7	4716-4727	implemented	_	_	_	_
35-8	4728-4733	based	_	_	_	_
35-9	4734-4736	on	_	_	_	_
35-10	4737-4740	the	abstract[247]	new[247]	_	_
35-11	4741-4745	TIME	abstract|abstract[247]	new|new[247]	_	_
35-12	4746-4753	concept	abstract[247]	new[247]	_	_
35-13	4754-4755	.	_	_	_	_

#Text=The use of negative pressure wound therapy ( NPWT ) is effective in shrinking the wound , reducing exudate and bacteria , and stimulating neoangigenesis , specialized dressings , in the case of superficial and penetrative lesions that do not qualify for surgery .
36-1	4756-4759	The	abstract[248]	new[248]	_	_
36-2	4760-4763	use	abstract[248]	new[248]	_	_
36-3	4764-4766	of	abstract[248]	new[248]	_	_
36-4	4767-4775	negative	abstract[248]|event[251]	new[248]|giv[251]	_	_
36-5	4776-4784	pressure	abstract[248]|abstract|event[251]	new[248]|giv|giv[251]	_	_
36-6	4785-4790	wound	abstract[248]|abstract|event[251]	new[248]|giv|giv[251]	coref	36-15[253_0]
36-7	4791-4798	therapy	abstract[248]|event[251]	new[248]|giv[251]	_	_
36-8	4799-4800	(	_	_	_	_
36-9	4801-4805	NPWT	object	new	_	_
36-10	4806-4807	)	_	_	_	_
36-11	4808-4810	is	_	_	_	_
36-12	4811-4820	effective	_	_	_	_
36-13	4821-4823	in	_	_	_	_
36-14	4824-4833	shrinking	_	_	_	_
36-15	4834-4837	the	object[253]	giv[253]	_	_
36-16	4838-4843	wound	object[253]	giv[253]	_	_
36-17	4844-4845	,	_	_	_	_
36-18	4846-4854	reducing	_	_	_	_
36-19	4855-4862	exudate	object	giv	_	_
36-20	4863-4866	and	_	_	_	_
36-21	4867-4875	bacteria	plant	new	_	_
36-22	4876-4877	,	_	_	_	_
36-23	4878-4881	and	_	_	_	_
36-24	4882-4893	stimulating	abstract[256]	new[256]	_	_
36-25	4894-4908	neoangigenesis	abstract[256]	new[256]	_	_
36-26	4909-4910	,	_	_	_	_
36-27	4911-4922	specialized	abstract[257]	new[257]	coref	37-23[264_257]
36-28	4923-4932	dressings	abstract[257]	new[257]	_	_
36-29	4933-4934	,	_	_	_	_
36-30	4935-4937	in	_	_	_	_
36-31	4938-4941	the	_	_	_	_
36-32	4942-4946	case	_	_	_	_
36-33	4947-4949	of	_	_	_	_
36-34	4950-4961	superficial	object[258]	new[258]	_	_
36-35	4962-4965	and	object[258]	new[258]	_	_
36-36	4966-4977	penetrative	object[258]	new[258]	_	_
36-37	4978-4985	lesions	object[258]	new[258]	_	_
36-38	4986-4990	that	_	_	_	_
36-39	4991-4993	do	_	_	_	_
36-40	4994-4997	not	_	_	_	_
36-41	4998-5005	qualify	_	_	_	_
36-42	5006-5009	for	_	_	_	_
36-43	5010-5017	surgery	event	new	_	_
36-44	5018-5019	.	_	_	_	_

#Text=There are clinical situations , especially in terminally ill patients , in which wounds debrided from necrotic tissue are only managed with dressings , due to the patient ’s condition and poor prognosis .
37-1	5020-5025	There	_	_	_	_
37-2	5026-5029	are	_	_	_	_
37-3	5030-5038	clinical	abstract[260]	new[260]	_	_
37-4	5039-5049	situations	abstract[260]	new[260]	_	_
37-5	5050-5051	,	abstract[260]	new[260]	_	_
37-6	5052-5062	especially	abstract[260]|person[261]	new[260]|new[261]	_	_
37-7	5063-5065	in	abstract[260]|person[261]	new[260]|new[261]	_	_
37-8	5066-5076	terminally	abstract[260]|person[261]	new[260]|new[261]	_	_
37-9	5077-5080	ill	abstract[260]|person[261]	new[260]|new[261]	_	_
37-10	5081-5089	patients	abstract[260]|person[261]	new[260]|new[261]	_	_
37-11	5090-5091	,	_	_	_	_
37-12	5092-5094	in	_	_	_	_
37-13	5095-5100	which	_	_	_	_
37-14	5101-5107	wounds	abstract	new	_	_
37-15	5108-5116	debrided	_	_	_	_
37-16	5117-5121	from	_	_	_	_
37-17	5122-5130	necrotic	object[263]	giv[263]	_	_
37-18	5131-5137	tissue	object[263]	giv[263]	_	_
37-19	5138-5141	are	_	_	_	_
37-20	5142-5146	only	_	_	_	_
37-21	5147-5154	managed	_	_	_	_
37-22	5155-5159	with	_	_	_	_
37-23	5160-5169	dressings	abstract[264]	giv[264]	_	_
37-24	5170-5171	,	abstract[264]	giv[264]	_	_
37-25	5172-5175	due	abstract[264]	giv[264]	_	_
37-26	5176-5178	to	_	_	_	_
37-27	5179-5182	the	abstract[266]	giv[266]	_	_
37-28	5183-5190	patient	person[265]|abstract[266]	giv[265]|giv[266]	_	_
37-29	5191-5193	’s	person[265]|abstract[266]	giv[265]|giv[266]	_	_
37-30	5194-5203	condition	abstract[266]	giv[266]	_	_
37-31	5204-5207	and	_	_	_	_
37-32	5208-5212	poor	abstract[267]	new[267]	_	_
37-33	5213-5222	prognosis	abstract[267]	new[267]	_	_
37-34	5223-5224	.	_	_	_	_
